Iridian Asset Management LLC Avadel Pharmaceuticals PLC Call Options Transaction History

Iridian Asset Management LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 02, 2022	SELL	$5.46 - $8.29 $468,468 - $711,281	-85,800 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$7.34 - $11.18 $538,022 - $819,494	-73,300 Reduced 46.07%	85,800 $693,000
Q1 2020 May 11, 2020	BUY	$4.06 - $10.64 $645,945 - $1.69 Million	159,100 New	159,100 $1.26 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Iridian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Iridian Asset Management LLC with notifications on news.